Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Septerna, Inc.SEPN · Entity 2452 | SVP, Drug Discovery | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Septerna, Inc.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,412 |
Ending reported balance
After 2026-09-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 3,333 · Balance 99,745 Row 2 · 2026-09-01 · Sale · Disposed 3,333 · Balance 96,412 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.34 to $38.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.76 · Expires 2034-03-19 | Direct | 9,085 |
Reported balance
After 2026-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-01 · Exercise / conversion · Disposed 3,333 · Balance 9,085 F3: 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.34 to $38.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 23:01 UTC | Septerna, Inc. SEPN · Entity 2452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,333 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001193125-26-382267 · ownership.xml · derivative · entry 3 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,085 Underlying: Common Stock · 3,333 shares Expires 2034-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 23:01 UTC | Septerna, Inc. SEPN · Entity 2452 | SaleCommon Stock | 3,333 | $37.83 | $126,077.72 |
DisclosureSEC source: 0001193125-26-382267 · ownership.xml · nonDerivative · entry 2 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,412 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.34 to $38.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 23:01 UTC | Septerna, Inc. SEPN · Entity 2452 | Exercise / conversionCommon Stock | 3,333 | $2.76 | $9,199.08 |
DisclosureSEC source: 0001193125-26-382267 · ownership.xml · nonDerivative · entry 1 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 23:00 UTC | Septerna, Inc. SEPN · Entity 2452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,518 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001193125-26-335820 · ownership.xml · derivative · entry 6 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,418 Underlying: Common Stock · 1,518 shares Expires 2034-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 23:00 UTC | Septerna, Inc. SEPN · Entity 2452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,816 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001193125-26-335820 · ownership.xml · derivative · entry 5 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,227 Underlying: Common Stock · 1,816 shares Expires 2033-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 23:00 UTC | Septerna, Inc. SEPN · Entity 2452 | SaleCommon Stock | 2,334 | $34.68 | $80,944.29 |
DisclosureSEC source: 0001193125-26-335820 · ownership.xml · nonDerivative · entry 4 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,412 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.43 to $35.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 23:00 UTC | Septerna, Inc. SEPN · Entity 2452 | SaleCommon Stock | 1,000 | $33.98 | $33,975.60 |
DisclosureSEC source: 0001193125-26-335820 · ownership.xml · nonDerivative · entry 3 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,746 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.39 to $34.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 23:00 UTC | Septerna, Inc. SEPN · Entity 2452 | Exercise / conversionCommon Stock | 1,518 | $2.76 | $4,189.68 |
DisclosureSEC source: 0001193125-26-335820 · ownership.xml · nonDerivative · entry 2 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 23:00 UTC | Septerna, Inc. SEPN · Entity 2452 | Exercise / conversionCommon Stock | 1,816 | $2.76 | $5,012.16 |
DisclosureSEC source: 0001193125-26-335820 · ownership.xml · nonDerivative · entry 1 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 23:00 UTC | Septerna, Inc. SEPN · Entity 2452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,333 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001193125-26-295106 · ownership.xml · derivative · entry 4 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,043 Underlying: Common Stock · 3,333 shares Expires 2033-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 23:00 UTC | Septerna, Inc. SEPN · Entity 2452 | SaleCommon Stock | 1,233 | $34.81 | $42,925.79 |
DisclosureSEC source: 0001193125-26-295106 · ownership.xml · nonDerivative · entry 3 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,412 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.52 to $35.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 23:00 UTC | Septerna, Inc. SEPN · Entity 2452 | SaleCommon Stock | 2,100 | $34.10 | $71,602.44 |
DisclosureSEC source: 0001193125-26-295106 · ownership.xml · nonDerivative · entry 2 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,645 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.49 to $34.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 23:00 UTC | Septerna, Inc. SEPN · Entity 2452 | Exercise / conversionCommon Stock | 3,333 | $2.76 | $9,199.08 |
DisclosureSEC source: 0001193125-26-295106 · ownership.xml · nonDerivative · entry 1 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 23:24 UTC | Septerna, Inc. SEPN · Entity 2452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,471 | $0.00 Strike: $11.70 | $0.00 |
DisclosureSEC source: 0001193125-26-281461 · ownership.xml · derivative · entry 6 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,529 Underlying: Common Stock · 4,471 shares Expires 2035-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 23:24 UTC | Septerna, Inc. SEPN · Entity 2452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,529 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001193125-26-281461 · ownership.xml · derivative · entry 5 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,376 Underlying: Common Stock · 10,529 shares Expires 2033-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 23:24 UTC | Septerna, Inc. SEPN · Entity 2452 | SaleCommon Stock | 7,000 | $35.97 | $251,780.90 |
DisclosureSEC source: 0001193125-26-281461 · ownership.xml · nonDerivative · entry 4 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,412 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.71 to $36.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 23:24 UTC | Septerna, Inc. SEPN · Entity 2452 | SaleCommon Stock | 8,000 | $35.10 | $280,800.80 |
DisclosureSEC source: 0001193125-26-281461 · ownership.xml · nonDerivative · entry 3 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,412 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.70 to $35.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 23:24 UTC | Septerna, Inc. SEPN · Entity 2452 | Exercise / conversionCommon Stock | 4,471 | $11.70 | $52,310.70 |
DisclosureSEC source: 0001193125-26-281461 · ownership.xml · nonDerivative · entry 2 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 23:24 UTC | Septerna, Inc. SEPN · Entity 2452 | Exercise / conversionCommon Stock | 10,529 | $2.76 | $29,060.04 |
DisclosureSEC source: 0001193125-26-281461 · ownership.xml · nonDerivative · entry 1 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on April 30, 2026 in a transaction that was exempt under Rule 16b-3(c). Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:17 UTC | Septerna, Inc. SEPN · Entity 2452 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $25.41 | $0.00 |
DisclosureSEC source: 0001193125-26-045118 · ownership.xml · derivative · entry 1 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-02-05 F1 · derivative.exercise_date: 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| November 10, 2025 Filed Nov 14, 2025 01:13 UTC | Septerna, Inc. SEPN · Entity 2452 | SaleCommon Stock | 3,501 | $18.06 | $63,223.16 |
DisclosureSEC source: 0001193125-25-280756 · ownership.xml · nonDerivative · entry 1 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,911 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.04 to $18.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on October 31, 2025 in transactions that were exempt under Rule 16b-3(c). Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 23:03 UTC | Septerna, Inc. SEPN · Entity 2452 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $11.70 | $0.00 |
DisclosureSEC source: 0000950170-25-106792 · ownership.xml · derivative · entry 1 Long Daniel D. · CIK 0002040349 · SVP, Drug Discovery 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-08-06 F1 · derivative.exercise_date: 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.